EE05282B1 - ™strogeeni-tsklodekstriini komplekside kompositsioonid - Google Patents

™strogeeni-tsklodekstriini komplekside kompositsioonid

Info

Publication number
EE05282B1
EE05282B1 EEP200300298A EEP200300298A EE05282B1 EE 05282 B1 EE05282 B1 EE 05282B1 EE P200300298 A EEP200300298 A EE P200300298A EE P200300298 A EEP200300298 A EE P200300298A EE 05282 B1 EE05282 B1 EE 05282B1
Authority
EE
Estonia
Prior art keywords
compositions
complexes
strogen
clodextrin
dosage forms
Prior art date
Application number
EEP200300298A
Other languages
English (en)
Inventor
Backensfeld Thomas
Heil Wolfgang
Lipp Ralph
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200300298A publication Critical patent/EE200300298A/et
Publication of EE05282B1 publication Critical patent/EE05282B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
EEP200300298A 2000-12-20 2001-12-20 ™strogeeni-tsklodekstriini komplekside kompositsioonid EE05282B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25648400P 2000-12-20 2000-12-20
EP00610135A EP1216713A1 (en) 2000-12-20 2000-12-20 Compositions of estrogen-cyclodextrin complexes
PCT/IB2001/002605 WO2002049675A1 (en) 2000-12-20 2001-12-20 Compositions of estrogen-cyclodextrin complexes

Publications (2)

Publication Number Publication Date
EE200300298A EE200300298A (et) 2003-12-15
EE05282B1 true EE05282B1 (et) 2010-04-15

Family

ID=26073713

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300298A EE05282B1 (et) 2000-12-20 2001-12-20 ™strogeeni-tsklodekstriini komplekside kompositsioonid

Country Status (30)

Country Link
US (3) US6958326B2 (et)
EP (3) EP1216713A1 (et)
JP (2) JP4782364B2 (et)
KR (3) KR20080108161A (et)
CN (1) CN1268396C (et)
AT (1) ATE311204T1 (et)
AU (3) AU1941802A (et)
BG (1) BG66050B1 (et)
BR (1) BRPI0116417B8 (et)
CA (2) CA2432151C (et)
CY (2) CY1106071T1 (et)
CZ (2) CZ307876B6 (et)
DE (1) DE60115499T2 (et)
DK (2) DK1632237T3 (et)
EA (2) EA011275B1 (et)
EE (1) EE05282B1 (et)
ES (2) ES2639537T3 (et)
HK (1) HK1055397A1 (et)
HR (2) HRP20030592B1 (et)
HU (2) HU230299B1 (et)
IL (3) IL156437A0 (et)
LT (1) LT1632237T (et)
ME (1) MEP38108A (et)
MX (1) MXPA03005636A (et)
NO (1) NO332726B1 (et)
NZ (1) NZ526847A (et)
RS (2) RS57801B1 (et)
SI (2) SI1353700T1 (et)
SK (1) SK287500B6 (et)
WO (1) WO2002049675A1 (et)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
AU2004270188B8 (en) 2003-09-03 2010-04-29 Mallinckrodt Inc. Granular sustained release preparation and production thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US20070287684A1 (en) * 2006-05-22 2007-12-13 Irshad Chaudry Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE502006003892D1 (de) * 2006-08-10 2009-07-16 Bayer Schering Pharma Ag Perorale Arzneiform mit Dienogest und Ethinylestradiol zur Kontrazeption
HUP0700826A3 (en) * 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
EP2293779A1 (en) * 2008-04-24 2011-03-16 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
JP5852639B2 (ja) 2010-04-15 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ｈｒｔのための低用量固体経口投与形態
KR20180018827A (ko) 2010-04-15 2018-02-21 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US8586527B2 (en) 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
CN102512688A (zh) * 2011-12-29 2012-06-27 上海新华联制药有限公司 尼尔雌醇-β-环糊精包合物及制剂和制备方法
IL298436B1 (en) 2012-01-23 2024-03-01 Sage Therapeutics Inc Pharmaceutical preparations that include allopregnanolone
RU2494757C1 (ru) * 2012-04-12 2013-10-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент дезоксирибонуклеазу, альфа-фетопротеин и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
US9359451B2 (en) 2012-05-15 2016-06-07 The Uab Research Foundation Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
IL304912A (en) 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PL3310346T3 (pl) 2015-06-18 2021-10-25 Estetra Sprl Dyspergowalna w ustach tabletka zawierająca estetrol
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
TN2017000499A1 (en) 2015-06-18 2019-04-12 Mithra Pharmaceuticals S A Orodispersible dosage unit containing an estetrol component
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US11147771B2 (en) 2015-06-18 2021-10-19 Estetra Sprl Orodispersible dosage unit containing an estetrol component
RU2640081C1 (ru) * 2016-07-11 2017-12-26 Общество с ограниченной ответственностью "ЛАЙФ САЙНСЕС ОХФК" Фармацевтическая композиция и лекарственное средство на основе клатратного комплекса N-карбамоилметил-4-фенил-2-пирролидон или 4-фенилпирацетам с циклодекстрином, способы его получения (варианты)
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
EP3666260A1 (en) * 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
CN114225050B (zh) * 2022-01-29 2022-12-13 国家卫生健康委科学技术研究所 炔雌醇环糊精复合物的制备及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
JPS5527558A (en) * 1978-08-18 1980-02-27 Tokico Ltd Gas spring
HU190356B (en) 1981-10-27 1986-08-28 Richter Gedeon Vegyeszeti Termekek Gyara Rt,Hu Process for preparing steroid-gamma-cyclodextrin inclusion complexes with high water-solubility
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5229370A (en) 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
JP3207212B2 (ja) 1991-03-01 2001-09-10 久光製薬株式会社 吸収促進剤およびこれを含有する外用剤
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
CZ289081B6 (cs) * 1994-09-22 2001-10-17 Akzo Nobel N. V. Způsob výroby farmaceutické lékové formy a tableta
JP2920611B2 (ja) 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
ATE271386T1 (de) * 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
DE19848303A1 (de) * 1998-10-14 2000-04-20 Schering Ag Kombination aus Gestagenen und Zuckern
EP1036510B1 (en) * 1999-03-18 2004-01-07 Bristol-Myers Squibb Company Vitamin formulation for cardiovascular health
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物
ATE429231T1 (de) * 1999-08-31 2009-05-15 Bayer Schering Pharma Ag Pharmazeutische kombination von ethinylestradiol und drospirenon als empfängnisverhütendes mittel
BR0107683A (pt) * 2000-01-18 2002-11-12 Schering Ag Drospirenona para terapia de reposição de hormÈnio

Also Published As

Publication number Publication date
CA2432151C (en) 2012-01-24
ATE311204T1 (de) 2005-12-15
EP1632237A2 (en) 2006-03-08
EA007411B1 (ru) 2006-10-27
DE60115499D1 (de) 2006-01-05
YU51203A (sh) 2006-08-17
JP4782364B2 (ja) 2011-09-28
AU2006225232B2 (en) 2007-09-27
BR0116417A (pt) 2003-12-30
CA2432151A1 (en) 2002-06-27
US20020173487A1 (en) 2002-11-21
MEP38108A (en) 2011-02-10
SK9142003A3 (en) 2004-03-02
EP1216713A1 (en) 2002-06-26
HU230299B1 (hu) 2015-12-28
DK1353700T3 (da) 2006-03-20
EP1632237A3 (en) 2006-04-12
EA011275B1 (ru) 2009-02-27
SI1632237T1 (sl) 2017-10-30
KR20030070905A (ko) 2003-09-02
LT1632237T (lt) 2017-10-10
EP1632237B1 (en) 2017-06-21
IL188250A0 (en) 2008-03-20
EP1353700A1 (en) 2003-10-22
HUP1500492A2 (en) 2003-11-28
HRP20030592A2 (en) 2005-06-30
NO20032805D0 (no) 2003-06-19
US6958326B2 (en) 2005-10-25
AU2002219418C1 (en) 2002-07-01
AU1941802A (en) 2002-07-01
HUP0302499A3 (en) 2012-02-28
WO2002049675A1 (en) 2002-06-27
HU230745B1 (hu) 2018-01-29
NZ526847A (en) 2005-01-28
US7163931B2 (en) 2007-01-16
BRPI0116417B8 (pt) 2021-05-25
CZ307876B6 (cs) 2019-07-10
IL156437A0 (en) 2004-01-04
MXPA03005636A (es) 2003-10-06
SI1353700T1 (sl) 2006-02-28
CN1268396C (zh) 2006-08-09
RS20090299A (en) 2009-11-10
CY1106071T1 (el) 2011-06-08
HRP20070198A2 (en) 2007-09-30
ES2639537T3 (es) 2017-10-27
CA2756207A1 (en) 2002-06-27
HRP20070198B1 (hr) 2019-04-19
PL361799A1 (en) 2004-10-04
NO20032805L (no) 2003-08-20
RS57801B1 (sr) 2018-12-31
EA200300669A1 (ru) 2004-02-26
US20050182024A1 (en) 2005-08-18
RS50362B (sr) 2009-11-10
JP5015976B2 (ja) 2012-09-05
BRPI0116417B1 (pt) 2019-04-02
CZ305671B6 (cs) 2016-02-03
NO332726B1 (no) 2012-12-27
KR20080108161A (ko) 2008-12-11
CZ20031985A3 (cs) 2003-11-12
BG66050B1 (bg) 2010-12-30
IL156437A (en) 2008-03-20
DE60115499T2 (de) 2006-08-10
KR101275372B1 (ko) 2013-06-14
HUP0302499A2 (hu) 2003-11-28
US7569557B2 (en) 2009-08-04
SK287500B6 (sk) 2010-12-07
JP2009102424A (ja) 2009-05-14
EE200300298A (et) 2003-12-15
CY1119806T1 (el) 2018-06-27
AU2002219418B2 (en) 2006-07-06
IL188250A (en) 2012-02-29
CZ2015831A3 (et) 2003-11-12
AU2006225232A1 (en) 2006-10-26
BG108002A (bg) 2004-08-31
ES2249387T3 (es) 2006-04-01
HK1055397A1 (en) 2004-01-09
EA200600884A1 (ru) 2006-10-27
HRP20030592B1 (en) 2007-05-31
AU2006225232B8 (en) 2007-11-15
EP1353700B1 (en) 2005-11-30
CA2756207C (en) 2014-02-11
CN1482921A (zh) 2004-03-17
JP2004518656A (ja) 2004-06-24
KR20090120015A (ko) 2009-11-23
US20070093451A1 (en) 2007-04-26
DK1632237T3 (en) 2017-09-25

Similar Documents

Publication Publication Date Title
EE05282B1 (et) ™strogeeni-tsklodekstriini komplekside kompositsioonid
DE60112609D1 (en) Pyrazolopyridine
HK1046403A1 (en) Nematicidal trifluorobutenes.
AU3652102A (en) Compounds and their uses
MXPA02012891A (es) Composiciones farmaceuticas de agentes estrogenicos.
DE60112330D1 (en) Pyrazolopyridinderivate
GB0011203D0 (en) Chemical compounds
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
MXPA02012493A (es) 1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales.
CY1105798T1 (el) Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
AU2002248531A1 (en) Pyrazolopyriadine derivatives
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
MD1473G2 (ro) Remediu antiherpetic
SE0001631D0 (sv) New use
DK1444247T3 (da) Tibolonformuleringer
PL365687A1 (en) Novel trioxepan compounds
BR0113357A (pt) Composição oral
MEP38208A (en) COMPOSITION CONTAINING AN ANDROGENOUS 11beta-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
GB1A Change in the ownership or in the address of the owner